title: Four cardiac hormones eliminate up to 82% of human medullary thyroid carcinoma cells within 24 hours.
abstract: Four cardiac hormones, i.e., atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide, which have anticancer effects, were evaluated for the first time on any endocrine cancer to determine if they have anticancer effects in an endocrine cancer. These four cardiac hormones were evaluated for their anticancer, DNA synthesis, and receptor status in human medullary thyroid cancer cells. There was a significant (p < 0.001) decrease in human medullary thyroid cancer cells with each 10-fold increase from 1 to 100 microM of the four cardiac hormones. There was an 81%, 68%, 71%, and 66% elimination within 24 h of medullary thyroid cancer cells secondary to vessel dilator, kaliuretic peptide, atrial natriuretic peptide, and long-acting natriuretic peptide, respectively (p < 0.0001). Three days after treatment with these peptide hormones, there was no proliferation of the medullary thyroid cancer cells. These cardiac hormones decreased DNA synthesis in the medullary thyroid cells from 65% to 84% (p < 0.0001). Western blots revealed natriuretic peptide receptors-A and -C were present in human medullary thyroid cancer cells. These results indicate the four cardiac hormones have potent anticancer effects by eliminating up to 82% of human medullary thyroid carcinoma cells within 24 h of treatment.
authors.affiliation: Department of Internal Medicine, James A. Haley Veterans Medical Center, Tampa, FL 33612, USA.
authors.forename: Ehrentraud J
authors.initials: EJ
authors.lastname: Eichelbaum
authors.forename: Brian A
authors.initials: BA
authors.lastname: Vesely
authors.forename: Abdel A
authors.initials: AA
authors.lastname: Alli
authors.forename: Ying
authors.initials: Y
authors.lastname: Sun
authors.forename: William R
authors.initials: WR
authors.lastname: Gower
authors.forename: David L
authors.initials: DL
authors.lastname: Vesely
mesh_terms: D009320:Atrial Natriuretic Factor / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D018276:Carcinoma, Medullary / Q000188:drug therapy* / Q000378:metabolism; D002452:Cell Count; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004247:DNA / Q000096:biosynthesis; D006162:Guanylate Cyclase / Q000378:metabolism; D006801:Humans; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D011498:Protein Precursors / Q000494:pharmacology / Q000627:therapeutic use; D017461:Receptors, Atrial Natriuretic Factor / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D019384:Nucleic Acid Synthesis Inhibitors; D010446:Peptide Fragments; D011498:Protein Precursors; C075322:atrial natriuretic factor precursor (79-98); C054547:atrial natriuretic factor prohormone (1-30), human; C054548:atrial natriuretic factor prohormone (31-67); D009320:Atrial Natriuretic Factor; D004247:DNA; D006162:Guanylate Cyclase; D017461:Receptors, Atrial Natriuretic Factor; C091715:atrial natriuretic factor receptor A; C073616:atrial natriuretic factor receptor C